<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03779555</url>
  </required_header>
  <id_info>
    <org_study_id>201812141</org_study_id>
    <nct_id>NCT03779555</nct_id>
  </id_info>
  <brief_title>Lenalidomide Adherence in Older Adults</brief_title>
  <official_title>Lenalidomide Adherence in Older Adults: A Pilot Prospective Cohort Study of Oral Therapy for Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alliance for Clinical Trials in Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To describe patterns of adherence and pilot baseline measures to investigate factors
      associated with lower adherence to lenalidomide in older adults with myeloma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 13, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adherence rate as measured by the number of days in which the lenalidomide pill bottle was open</measure>
    <time_frame>Through completion of study (estimated to be 3 months)</time_frame>
    <description>-Participants will be given a pill diary in which they will record if they opened the pill bottle without taking a medication (e.g. to ascertain remaining supply) to adjust the adherence rate accordingly</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adherence rate as measured by a modified Brief Adherence Rating Scale</measure>
    <time_frame>Through completion of study (estimated to be 3 months)</time_frame>
    <description>Participants will fill out a brief survey about taking lenalidomide and an estimate of their adherence using a visual analog scale
Scored 0-100%, 0% = lenalidomide not taken on any days and 100% = lenalidomide taken every day</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Patients taking lenalidomide for multiple myeloma</arm_group_label>
    <description>-Patients will be seen at baseline, 1 month (+/- 1 week), 2 months (3-5 weeks following 1-month assessment), and 3 months (3-5 weeks after 2-month follow-up)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Medication Event Monitoring System</intervention_name>
    <description>-Microchipped bottle cap</description>
    <arm_group_label>Patients taking lenalidomide for multiple myeloma</arm_group_label>
    <other_name>MEMS</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants from Siteman Cancer Center and its satellite sites with multiple myeloma who
        are taking lenalidomide.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥65

          -  Receiving lenalidomide for treatment of multiple myeloma.

          -  Anticipated to receive ongoing care at Siteman Cancer Center and its satellite sites

          -  Able to read and understand English.

          -  Able to understand and willing to sign an IRB-approved written informed consent
             document.

        Exclusion Criteria:

          -  Estimated life expectancy &lt;6 months.

          -  Anticipated duration of lenalidomide therapy &lt;3 months.

          -  Residing in a nursing facility where their medications are administered to them OR
             patient reports they do not self-administer their own medications.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tanya Wildes, M.D., MSCI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tanya M Wildes, M.D., MSCI</last_name>
    <phone>314-273-3073</phone>
    <email>twildes@wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanya M Wildes, M.D., MSCI</last_name>
      <phone>314-273-3073</phone>
      <email>twildes@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Tanya M Wildes, M.D., MSCI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>December 17, 2018</study_first_submitted>
  <study_first_submitted_qc>December 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2018</study_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>What data will be shared?: Individual participant data that underlie the results reported in the final published manuscript after deidentification (text, tables, figures, and appendices). Participants who opted out of data sharing in the informed consent will not be included.
With whom will the data be shared?: Researchers who provide a methodologically sound proposal.
For what types of analyses?: To achieve aims in the approved proposal.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Beginning 3 months and ending 4 years following article publication.</ipd_time_frame>
    <ipd_access_criteria>Proposals should be directed to twildes@wustl.edu. To gain access, data requestors will need to sign a data access agreement and provide proof of appropriate regulatory approvals as necessary.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

